8 news items
ASLAN Pharmaceuticals Presents Late-Breaking Translational Data on Eblasakimab in COPD at the American Thoracic Society International Conference
ASLN
21 May 24
with COPD (COPD PCLS) were used to test constriction and dilation responses to different treatment conditions including IL-4, IL-13, methacholine
ASLAN Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update
ASLN
9 May 24
strong confidence in eblasakimab's potential to be a best-in-class treatment for AD patients even after they have had an inadequate response
ASLAN Pharmaceuticals to Present Additional Data From Interim Analysis of TREK-DX Phase 2 Study of Eblasakimab in Dupilumab-Experienced Atopic Dermatitis Patients During Virtual KOL Event
ASLN
7 May 24
to eblasakimab even after having an inadequate response to dupilumabData
ASLAN Pharmaceuticals Announces Expansion Of Its Collaboration With Zenyaku To Investigate The Biology Underlying Differential Effects Of Eblasakimab Compared To Other Biologics
ASLN
2 May 24
may respond to eblasakimab even after having an inadequate response to dupilumab
ASLAN Pharmaceuticals to Host KOL Panel Discussion on Treatment Options for Atopic Dermatitis Patients With an Inadequate Response to Dupilumab
ASLN
30 Apr 24
Patients with an Inadequate Response to Dupilumab: Exploring the Potential of Eblasakimab in this Sizable New Market", to be held on Tuesday
qn1s1qbpu5036kdwb9uw y1g8q30speux3jd11mmzny6ax51poocj7v4vt
ASLN
22 Apr 24
with eblasakimab that previously had an inadequate response to dupilumab, 66.7
4939nuflq4mttuyd66u1hvsg0thyzttgktpm3ag
ASLN
12 Apr 24
weeks. 56% (5/9) of patients with prior inadequate response to dupilumab achieved EASI-90 and 56% (5/9
kv728ur56akxqy6xbqxg74mhdjrend59p
ASLN
6 Mar 24
, eblasakimab was effective in restoring constriction in response to challenges with IL-4 and IL-13, and demonstrated rapid, formoterol-induced airway
- Prev
- 1
- Next